Brexpiprazole in patients with schizophrenia: overview of short- and long-term phase 3 controlled studies.

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Abstract

Review efficacy, safety, and tolerability of brexpiprazole in patients with schizophrenia in short- and long-term phase 3 studies.

Related collections

Author and article information

Journal

Journal ID (iso-abbrev): Acta Neuropsychiatr

Title: Acta neuropsychiatrica

Publisher: Cambridge University Press (CUP)

ISSN (Electronic): 1601-5215

ISSN (Print): 0924-2708

Publication date (Electronic): Nov 16 2016

Affiliations

[1 ] 1Semel Institute for Neuroscience,University of California Los Angeles,Los Angeles,CA,USA.

[2 ] 2H. Lundbeck A/S,Valby,Denmark.

[3 ] 3Otsuka Pharmaceutical Development & Commercialization Inc.,Princeton,NJ,USA.

Article

Publisher Item ID: S0924270816000570

DOI: 10.1017/neu.2016.57

PubMed ID: 27846922

SO-VID: 005121b8-9b13-4861-ad86-d0439fb40879

History

Keywords: PANSS,efficacy,maintenance,safety,schizophrenia

Data availability:

Keywords: PANSS, efficacy, maintenance, safety, schizophrenia

Comments

Comment on this article

scite_

Cited by 11

See all cited by